 required for filing an invesfigafional new drug (IND) application with the USFDA. To this effect, nanocurcumin (as single agent or in combination with gemcitabine) will be tested in a panel of low-passage gemcitabine-resistant patientderived orthotopic xenografts (
required for filing an invesfigafional new drug (IND) application with the USFDA. To this consequence, nanocurcumin (as individual agent or in combination with gemcitabine) will be tested in a panel of humble - passage gemcitabine - resistant patientderived orthotopic heterograft (
 reeuired for filing an invtsfigafional new beug (INV) applidation wkth the USFDA. To this effect, nqnocuecumin (as single agent or in colbinatiob wiuh gemcitabine) will be tested ih a pcnxl of low-passagg gemcitabina-resistant pathevtberived orthotopic xenografts (
required for filing an invesfigafional new drug with USFDA. To effect, nanocurcumin (as with will be tested a panel of gemcitabine-resistant patientderived orthotopic xenografts (
 required for filing an invesfIgafional nEw druG (INd) apPlIcatIon wIth the USFDA. To tHIs efFect, nanocurcumin (as singLe ageNt OR in cOMbInatiOn with gEMcITAbiNe) WiLl bE tEStEd in a PanEl of low-Passage gemCitAbIne-resistant PAtIentderiveD orThotopic xenoGraFts (
 required for filing an in vesfigafio nal n ewdru g(IND ) ap plication with theUSFDA. To this effect,  nano cu r cumi n  ( as si ngle ag e nt o r i nco mbi na t io n wit h g emcitab ine) willbete sted in a pa n el  of low-pa ssa ge gemcitabi ne- resist an t p a tient der ivedorthot o pic xe nografts(
 required_for filing_an invesfigafional new drug_(IND) application_with_the USFDA._To_this effect, nanocurcumin_(as single agent_or in combination with_gemcitabine) will be_tested_in a panel of low-passage gemcitabine-resistant patientderived orthotopic xenografts (